



## Medication Trend Updates and Formulary Changes – 4th Quarter 2018

*Review information on the CURES mandate, infusion care, new fluoroquinolones label warnings, and quarterly recommended drug list changes*

This update includes information regarding the mandatory use of California's Controlled Substance Utilization Review and Evaluation System (CURES), alternative sites of infusion care for commercial members, new risks on taking fluoroquinolones, and changes to the Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company (Health Net) commercial *Recommended Drug Lists (RDLs)*, *Medi-Cal RDL* and *Medicare Part D Formularies* for the fourth quarter of 2018.

### CURES CONSULTATION MANDATE

To improve opioid prescribing practices and reduce the risk of opioid use disorders (OUD), mandatory consultation of CURES became effective October 2, 2018. This mandate applies to:

- Any health care practitioner with both a Drug Enforcement Administration (DEA) Controlled Substance Registration Certificate and a California licensure as any one of the following:
  - Dentist, physician, naturopathic doctor, optometrist, osteopathic doctor, physician assistant, podiatrist, registered certified nurse midwife (furnishing), and registered nurse practitioner (furnishing).
- This requirement does not apply to veterinarians or pharmacists.

Health care practitioners must consult the CURES database to review a patient's controlled substance history before prescribing, ordering, administering, or furnishing a Schedule II–IV controlled substance for the first time and at least once every four months when the controlled substance is part of a continued treatment plan.

For more information and exemptions, refer to <https://oag.ca.gov/cures> or contact the CURES Program at [CURES@doj.ca.gov](mailto:CURES@doj.ca.gov) or (916) 210-3187.

### ALTERNATIVE SITES OF INFUSION CARE FOR COMMERCIAL MEMBERS ONLY

Health Net continually looks for ways to help our members better manage and obtain medication therapies. Patients being treated with any of the listed products in the table found in this section have the option to transition infusions from the hospital to the home or an ambulatory infusion suite (AIS). Alternate site of infusion care is part of a member's standard benefits.

Health Net has partnered with Coram® CVS Specialty™ Infusion Services as the designated provider for these infusions. Coram provides:

- Experience – More than 30 years of experience in specialized infusion care and demonstrated expertise in the delivery and administration of complex specialty infused medications.

THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

LINES OF BUSINESS:

- HMO/POS/HSP
- PPO
- EPO
- Medicare Advantage (HMO)
- Medi-Cal
  - Kern
    - Molina
  - Los Angeles
  - Riverside
  - Sacramento
  - San Bernardino
  - San Diego
  - San Joaquin
  - Stanislaus
  - Tulare

PROVIDER SERVICES

[provider\\_services@healthnet.com](mailto:provider_services@healthnet.com)

**EnhancedCare PPO (IFP)**

1-844-463-8188

[provider.healthnetcalifornia.com](mailto:provider.healthnetcalifornia.com)

**EnhancedCare PPO (SBG)**

1-844-463-8188

[provider.healthnet.com](mailto:provider.healthnet.com)

**Health Net Employer Group HMO, POS, HSP, PPO, & EPO**

1-800-641-7761

[provider.healthnet.com](mailto:provider.healthnet.com)

**IFP – CommunityCare HMO, PPO, PureCare HSP, PureCare One EPO**

1-888-926-2164

[provider.healthnetcalifornia.com](mailto:provider.healthnetcalifornia.com)

**Medicare (individual)**

1-800-929-9224

[provider.healthnetcalifornia.com](mailto:provider.healthnetcalifornia.com)

**Medicare (employer group)**

1-800-929-9224

[provider.healthnet.com](mailto:provider.healthnet.com)

**Medi-Cal – 1-800-675-6110**

[provider.healthnet.com](mailto:provider.healthnet.com)

PROVIDER COMMUNICATIONS

[provider.communications@healthnet.com](mailto:provider.communications@healthnet.com)

[healthnet.com](mailto:healthnet.com)

fax 1-800-937-6086

- Safety – Clinicians are certified and specialize in delivery of chronic and complex drug therapy and careful patient monitoring. Experienced nurses stay for the entire infusion duration ensuring patients receive high-level care.
- Convenience – In-home and AIS-based infusions are scheduled directly with patients enabling flexibility, independence and enhanced quality of life. Clinical support is available to patients 24 hours a day, seven days a week.
- Cost – Infusions may be provided at a lower cost to patients promoting compliance to therapy and ultimately improve outcomes and reduce health costs.

For patient referrals or additional information, contact Peter Tran, PharmD, at (714) 934-3362, Monday through Friday, 9:00 a.m. to 4:00 p.m., and reference the Site of Care Optimization of Therapeutic Infusion (SCOTI) Program.

The products eligible for alternate site of infusion care include:

Disorder	Product	Disorder	Product
Alpha-1 antitrypsin deficiency	Aralast NP	Immune deficiencies and related conditions	Bivigam®
	Glassia®		Carimune® NF
	Prolastin® -C		Cuvitru
	Zemaira®		Cytogam®
Asthma	Cinqair®		Flebogamma® Dif
Autoimmune	Actemra®		Gammagard liquid
	Cimzia® lyophilized powder		Gammagard S/D
	Entyvio®		Gammaked™
	Inflectra®		Gammaplex®
	Orencia®		Gamunex®-C
	Remicade®		Hyqvia
	Renflexis®		Hizentra®
	Rituxan®		Octagam®
Gout	Simponi Aria®		Privigen®
	Stelara®	Aldurazyme®	
Hereditary angioedema	Krystexxa®	Lysosomal storage	Cerezyme®
	Beriner®		Elaprase®
	Cinryze®		Elelyso®
	Kalbitor		Fabrazyme
Movement	Ruconest		Kanuma®
	Radicava®		Lumizyme®
Multiple sclerosis	Lemtrada®		Naglazyme®
	Ocrevus®		Vimizim®
	Tysabri®	Vpriv®	
Paroxysmal nocturnal hemoglobinuria	Soliris®	Systemic lupus erythematosus	Benlysta®

## FLUOROQUINOLONES ANTIBIOTICS LABEL WARNING UPDATES

In July 2018, the U.S. Food and Drug Administration (FDA) required new safety labeling changes for a class of antibiotics called fluoroquinolones based on a comprehensive review of the FDA's adverse event reports and case reports published in medical literature. The labeling changes are to increase awareness about the risks of mental health side effects, serious blood sugar disturbances, and to make the warnings on labels more consistent for all fluoroquinolones taken by mouth or given by injection.<sup>1</sup>

- Labeling changes of the fluoroquinolone class require listing mental health side effects separately from other central nervous system side effects. These side effects include disturbances in attention, disorientation, agitation, nervousness, memory impairment, and delirium.

<sup>1</sup> U.S. Food & Drug Administration at [www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm612995.htm](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm612995.htm).

- The potential risk of coma with hypoglycemia must now be included on the fluoroquinolone class labeling under the Blood Glucose Disturbances subsection due to instances found among users.

Health care providers and patients should consider all risks and benefits of fluoroquinolones and make an informed decision about their use. Remind patients to read the Medication Guide insert that comes with each fluoroquinolone prescription describing the safety issues associated with these medicines.

## RECOMMENDED DRUG LIST AND MEDICARE PART D FORMULARY CHANGES

The Health Net *Recommended Drug Lists (RDLs)* and *Formularies* for commercial and Medi-Cal members, and the *Medicare Part D Formularies* for Medicare members are reviewed each quarter by the Health Net Pharmacy and Therapeutics (P&T) Committee, which includes practicing physicians, pharmacists and other health care professionals, to determine medications to remain on or be moved to a different status. A list of some recent changes is provided beginning on page 4. The list contains brand-name prescription medications, status, alternatives, and comments for the fourth quarter of 2018.

Complete lists of the *RDLs* and *Medicare Part D Formularies* are available on the Health Net provider portal, as listed in the table below, by selecting *Pharmacy Information* or *Provider Library*. Other pharmacy-related provider updates, prior authorization criteria and pharmacy forms are also available online under *Pharmacy Information*.

## PHARMACY HELP LINE

For additional information regarding changes to the commercial Health Net *RDLs*, Health Net Medi-Cal *RDLs* or *Medicare Part D Formularies*, contact the appropriate pharmacy telephone numbers listed below:

- **Pharmacy Services** (commercial): 1-800-548-5524, option #3; fax 1-800-314-6223
- **Pharmacy Service Center** (Medi-Cal and Medicare): 1-800-867-6564; fax 1-800-977-8226
- **Health Net Clinical Pharmacy Line** (clinical programs): 1-800-782-2221

## ADDITIONAL INFORMATION

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center within 60 days at:

Line of Business	Telephone Number	Provider Portal	Email Address
ENHANCEDCARE PPO (IFP)	1-844-463-8188	provider.healthnetcalifornia.com	provider_services@healthnet.com
ENHANCEDCARE PPO (SBG)	1-844-463-8188	provider.healthnet.com	
HEALTH NET EMPLOYER GROUP HMO, POS, HSP, PPO, & EPO	1-800-641-7761	provider.healthnet.com	
IFP (COMMUNITYCARE HMO, PPO, PURECARE HSP, PURECARE ONE EPO)	1-888-926-2164	provider.healthnetcalifornia.com	
MEDICARE (INDIVIDUAL)	1-800-929-9224	provider.healthnetcalifornia.com	
MEDICARE (EMPLOYER GROUP)	1-800-929-9224	provider.healthnet.com	
MEDI-CAL	1-800-675-6110	provider.healthnet.com	N/A

**HEALTH NET RECOMMENDED DRUG LIST (RDL), MEDI-CAL RDL AND MEDICARE PART D FORMULARY CHANGES**

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial 3-Tier Plan (4-Tier Plan)	Medicare Part D Value <sup>1</sup>	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value <sup>1</sup> (Tier 1, 2, 3, 4 or 6)	Medi-Cal	
<b>ORAL MEDICATIONS</b>							
Benznidazole tablet	Tier 2 (Tier 2)	NF	NF				Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi (T. cruzi) in pediatric patients ages 2 to 12  For commercial line of business, age limit is 2 to 12
Solosec™ (secnidazole) oral granules	NF (NF)	NF	NF	Vaginal preparations: clindamycin (Cleocin®), metronidazole (MetroGel Vaginal,® Vandazole®)	Vaginal preparations: clindamycin (Cleocin)  Oral preparations:	Vaginal preparations: clindamycin (Cleocin), metronidazole (MetroGel Vaginal, Vandazole), Clindesse®  Oral preparations: metronidazole (Flagyl)	Treatment of bacterial vaginosis in adult women

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial 3-Tier Plan (4-Tier Plan)	Medicare Part D Value <sup>1</sup>	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value <sup>1</sup> (Tier 1, 2, 3, 4 or 6)	Medi-Cal	
<b>ORAL MEDICATIONS, CONTINUED</b>							
Steglatro™ (ertugliflozin) tablet	NP (NP)	Tier 4	F QL, EST	metformin, glyburide, glipizide, Jardiance®, Invokana®	metformin, glyburide, glipizide, Jardiance, Invokana	metformin, glyburide, glipizide, Jardiance**, Invokana**	<p>An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus</p> <p>For Medicare, maximum quantity limit is 1 tablet per day for the 15 mg tablet and 3 tablets per day for the 5 mg tablet</p> <p>Quantity limit is 1 tablet per day</p> <p>Step therapy requires a trial of metformin first</p>
Symdeko® (tezacaftor/ivacaftor; ivacaftor) tablet	NP * (SP *)	Tier 5 *	F *, **			Orkambi® *, **	Treatment of patients with cystic fibrosis ages 12 and older who are homozygous for the F508del mutation or who have at least one mutation in the CFTR gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence
Tavalisse™ (fostamatinib) tablet	NP * (SP *)	Tier 5 *	NF	dexamethasone, prednisone	dexamethasone, prednisone	dexamethasone, prednisone	Treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial 1 3-Tier Plan (4-Tier Plan)	Medicare Part D Value <sup>1</sup>	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value <sup>1</sup> (Tier 1, 2, 3, 4 or 6)	Medi-Cal	

#### OPHTHALMIC PREPARATIONS

Rhopressa® (netarsudil) ophthalmic solution	NF (NF)	NF	NF	latanoprost (Xalatan®), timolol (Timoptic®), brimonidine (Alphagan® P), dorzolamide (Trusopt®)	latanoprost (Xalatan), timolol (Timoptic), brimonidine (Alphagan P), dorzolamide (Trusopt)	latanoprost (Xalatan), timolol (Timoptic), brimonidine (Alphagan P), dorzolamide (Trusopt)	Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
--	---------	----	----	---	---	--	---

#### INJECTABLE PREPARATIONS

Crysvita® (burosumab) single-dose vial	Medical benefit *	Tier 5 *	Medical benefit *	calcitriol (Rocaltrol®), oral phosphate agent (K- Phos,® K-Phos Neutral®)	calcitriol (Rocaltrol)	calcitriol (Rocaltrol), oral phosphate agent (K-Phos, K-Phos Neutral)	Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients ages 1 and older
--	----------------------	----------	----------------------	---	---------------------------	--	--

<sup>1</sup>Medicare Part D Value Formulary = Health Net Seniority Plus Amber I (HMO SNP), Health Net Seniority Plus Amber II (HMO SNP), Health Net Health Heart (HMO).

\*Prior authorization (PA) is required to verify member eligibility and that the member satisfies clinical protocols to ensure appropriate use of the medication.

\*\*CCS = California Children's Services: refer to [www.dhs.ca.gov](http://www.dhs.ca.gov) for the local telephone number to determine member's coverage eligibility.

- F indicates formulary.
- NF indicates nonformulary; NP indicates nonpreferred. These medications require member-specific medical reasons why formulary medications cannot be considered. Requests are reviewed via Health Net's prior authorization process.
- QL indicates quantity limit.
- SP indicates specialty tier.
- EST indicates electronic step therapy.

# PROVIDER Update



Health Net®

CONTRACTUAL | NOVEMBER 2, 2018 | UPDATE 18-786sum | 2 PAGES

## Summary Update: Medication Trend Updates and Formulary Changes – 4th Quarter 2018

*Review information on the CURES mandate, infusion care, new fluoroquinolones label warnings, and quarterly recommended drug list changes*

This update includes information regarding the mandatory use of California's Controlled Substance Utilization Review and Evaluation System (CURES), alternative sites of infusion care for commercial members, new risks on taking fluoroquinolones, and changes to the Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company (Health Net) commercial *Recommended Drug Lists (RDLs)*, *Medi-Cal RDL* and *Medicare Part D Formularies* for the fourth quarter of 2018.

### CURES CONSULTATION MANDATE

Effective October 2, 2018, health care practitioners must consult the CURES database to review a patient's controlled substance history before prescribing a Schedule II–IV controlled substance for the first time and at least once every four months thereafter.

For more information and exemptions to this mandate, refer to <https://oag.ca.gov/cures> or contact the CURES Program at [CURES@doj.ca.gov](mailto:CURES@doj.ca.gov) or (916) 210-3187.

### CORAM® CVS SPECIALTY™ INFUSION SERVICES FOR COMMERCIAL MEMBERS ONLY

Commercial members being treated with specific products can transition infusions from the hospital, to the home or an ambulatory infusion suite (AIS) as part of their standard benefits. A list of eligible products is available in the complete provider update 18-786, *Medication Trend Updates and Formulary Changes – 4th Quarter 2018*.

To provide an alternate site of infusion care, Health Net has partnered with Coram® CVS Specialty™ Infusion Services, with over 30 years of experience, as the designated provider.

For patient referrals or additional information, contact Peter Tran, PharmD, at (714) 934-3362, Monday through Friday, 9:00 a.m. to 4:00 p.m., and reference the Site of Care Optimization of Therapeutic Infusion (SCOTI) Program.

### FLUROQUINOLONONES WARNING LABEL CHANGES

In July 2018, the U.S. Food and Drug Administration (FDA) required new safety labeling changes for a class of antibiotics called fluoroquinolones.<sup>1</sup> These changes make label

<sup>1</sup> U.S. Food & Drug Administration at [www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm612995.htm](http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm612995.htm).

THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

LINES OF BUSINESS:

- HMO/POS/HSP
- PPO
- EPO
- Medicare Advantage (HMO)
- Medi-Cal
  - Kern
  - Los Angeles
    - Molina
  - Riverside
  - Sacramento
  - San Bernardino
  - San Diego
  - San Joaquin
  - Stanislaus
  - Tulare

PROVIDER SERVICES  
[provider\\_services@healthnet.com](mailto:provider_services@healthnet.com)

**EnhancedCare PPO (IFP)**  
1-844-463-8188  
[provider.healthnetcalifornia.com](mailto:provider.healthnetcalifornia.com)  
**EnhancedCare PPO (SBG)**  
1-844-463-8188  
[provider.healthnet.com](mailto:provider.healthnet.com)  
**Health Net Employer Group HMO, POS, HSP, PPO, & EPO**  
1-800-641-7761  
[provider.healthnet.com](mailto:provider.healthnet.com)  
**IFP – CommunityCare HMO, PPO, PureCare HSP, PureCare One EPO**  
1-888-926-2164  
[provider.healthnetcalifornia.com](mailto:provider.healthnetcalifornia.com)  
**Medicare (individual)**  
1-800-929-9224  
[provider.healthnetcalifornia.com](mailto:provider.healthnetcalifornia.com)  
**Medicare (employer group)**  
1-800-929-9224  
[provider.healthnet.com](mailto:provider.healthnet.com)  
**Medi-Cal – 1-800-675-6110**  
[provider.healthnet.com](mailto:provider.healthnet.com)

PROVIDER COMMUNICATIONS  
[provider.communications@healthnet.com](mailto:provider.communications@healthnet.com)  
fax 1-800-937-6086

warnings more consistent for all fluoroquinolones taken by mouth or given by injection. The changes are:

- Listing mental health side effects – which include disturbances in attention, disorientation, agitation, nervousness, memory impairment, and delirium – separately from other central nervous system side effects.
- Adding the potential risk of coma with hypoglycemia under the Blood Glucose Disturbances subsection.

## CHANGES TO THE RECOMMENDED DRUG LIST AND MEDICARE PART D FORMULARIES

A list of recent changes to the Health Net *RDLs* and *Formularies* is available in the complete provider update 18-786. The list contains brand-name prescription medications, status, alternatives, and comments. Complete listings of the *RDLs* and *Medicare Part D Formularies* are available on the Health Net provider portal, as listed in the table below, by selecting *Pharmacy Information*.

## PHARMACY HELP LINE

For additional information regarding the commercial Health Net *RDLs*, Health Net Medi-Cal *RDLs* or *Medicare Part D Formularies*, contact the appropriate pharmacy telephone numbers listed below:

**Pharmacy Services** (commercial): 1-800-548-5524, option #3; fax 1-800-314-6223

**Pharmacy Service Center** (Medi-Cal and Medicare): 1-800-867-6564; fax 1-800-977-8226

**Health Net Clinical Pharmacy Line** (clinical programs): 1-800-782-2221

## ADDITIONAL INFORMATION

To obtain a comprehensive description of the above topics, the complete update, 18-786, is available on the Health Net provider portal, as listed in the table below, in the Provider Library under *Updates and Letters > 2018*; search for provider update 18-786. Providers who do not have access to the Internet may request a print copy of update 18-786 by contacting the Health Net Provider Communications Department by fax at 1-800-937-6086 or by email at [provider.communications@healthnet.com](mailto:provider.communications@healthnet.com).

For the most current version of the Health Net *RDLs*, visit the Health Net provider portal, as listed in the table below, under *Pharmacy Information > Drug Lists*.

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center within 60 days at:

Line of Business	Telephone Number	Provider Portal	Email Address
ENHANCEDCARE PPO (IFP)	1-844-463-8188	<a href="http://provider.healthnetcalifornia.com">provider.healthnetcalifornia.com</a>	<a href="mailto:provider_services@healthnet.com">provider_services@healthnet.com</a>
ENHANCEDCARE PPO (SBG)	1-844-463-8188	<a href="http://provider.healthnet.com">provider.healthnet.com</a>	
HEALTH NET EMPLOYER GROUP HMO, POS, HSP, PPO, & EPO	1-800-641-7761	<a href="http://provider.healthnet.com">provider.healthnet.com</a>	
IFP (COMMUNITYCARE HMO, PPO, PURECARE HSP, PURECARE ONE EPO)	1-888-926-2164	<a href="http://provider.healthnetcalifornia.com">provider.healthnetcalifornia.com</a>	
MEDICARE (INDIVIDUAL)	1-800-929-9224	<a href="http://provider.healthnetcalifornia.com">provider.healthnetcalifornia.com</a>	
MEDICARE (EMPLOYER GROUP)	1-800-929-9224	<a href="http://provider.healthnet.com">provider.healthnet.com</a>	
MEDI-CAL	1-800-675-6110	<a href="http://provider.healthnet.com">provider.healthnet.com</a>	N/A